Abstract: Provided is a controller, an air conditioner, and a high-pressure protection circuit. The controller includes a first rectifier unit, a power conversion unit, a high pressure switch (HPS) wiring terminal, a low-voltage control unit, and a high-voltage operating unit. An input end of the first rectifier unit is capable of being electrically connected to an input power supply. An output end of the first rectifier unit is electrically connected to an input end of the power conversion unit. An output end of the power conversion unit is electrically connected to a power supply end of the low-voltage control unit. The HPS wiring terminal is connected to the front end of the power supply end of the low-voltage control. The controller has a function of high-pressure protection.

Abstract: Provided is a controller, an air conditioner, and a high-pressure protection circuit. The controller includes a first rectifier unit, a power conversion unit, a high pressure switch (HPS) wiring terminal, a low-voltage control unit, and a high-voltage operating unit. An input end of the first rectifier unit is capable of being electrically connected to an input power supply. An output end of the first rectifier unit is electrically connected to an input end of the power conversion unit. An output end of the power conversion unit is electrically connected to a power supply end of the low-voltage control unit. The HPS wiring terminal is connected to the front end of the power supply end of the low-voltage control. The controller has a function of high-pressure protection.

Abstract: The present invention provides an application of lncRNAs ENST00000607393 siRNA in preparing a preparation for treating glaucoma. The present invention clarifies the correlation between the expression level of ENST00000607393 and the calcification of human primary trabecular meshwork cells. The expression level of ENST00000607393 in human primary trabecular meshwork cells is firstly down-regulated to 46.21% of a control group by siRNA interference. Under the condition of intervening with the cells by a 500 ?mol/L hydrogen peroxide solution for 48 hours, it is observed that compared with the control group, the down-regulation of ENST00000607393 expression can significantly decrease the ALP activity in human primary trabecular meshwork cells, and thus significantly decrease the calcification level of human primary trabecular meshwork cells to play a role of treating or preventing glaucoma.

Abstract: The present invention provides two molecular markers, lncRNAs ENST00000607393 and lncRNAs ENST00000508241, diagnostic kits and applications for glaucoma diagnosis. Compared with people in a control group, the expressions of lncRNAs: ENST00000607393 are all up-regulated in aqueous humors, irises and serums of patients with glaucoma, and the expression of lncRNAs: ENST00000508241 is up-regulated in aqueous humors of patients with glaucoma. It indicates that ENST00000607393 and ENST00000508241 are highly expressed lncRNAs in glaucoma and are biomarkers that contribute to the diagnosis of glaucoma. The present invention provides a strong molecular biology basis for the diagnosis of glaucoma, and has far-reaching clinical significance and generalization performance.

Abstract: The present invention provides an application of lncRNAs ENST00000607393 siRNA in preparing a preparation for treating glaucoma. The present invention clarifies the correlation between the expression level of ENST00000607393 and the calcification of human primary trabecular meshwork cells. The expression level of ENST00000607393 in human primary trabecular meshwork cells is firstly down-regulated to 46.21% of a control group by siRNA interference. Under the condition of intervening with the cells by a 500 ?mol/L hydrogen peroxide solution for 48 hours, it is observed that compared with the control group, the down-regulation of ENST00000607393 expression can significantly decrease the ALP activity in human primary trabecular meshwork cells, and thus significantly decrease the calcification level of human primary trabecular meshwork cells to play a role of treating or preventing glaucoma.

Abstract: The present invention discloses three molecular markers kits and applications for glaucoma diagnosis. The expressions of lncRNAs: T342877, lncRNAs: NR_026887, and lncRNAs: TCONS_00025577 are up-regulated in aqueous humors of patients with glaucoma compared with people in a control group. It indicates that lncRNAs: T342877, lncRNAs: NR_026887, and lncRNAs: TCONS_00025577 are highly expressed lncRNAs in glaucoma and are biomarkers that contribute to the diagnosis of glaucoma. The present invention provides a strong molecular biology basis for the diagnosis of glaucoma, and has far-reaching clinical significance and generalization performance.

Abstract: The present invention discloses two molecular markers, kits and applications for glaucoma diagnosis. Compared with people in a control group, the expressions of lncRNAs: T267384 are all up-regulated in aqueous humors and serums of patients with glaucoma, and the expression of lncRNAs: ENST00000564363 is up-regulated in aqueous humors of patients with glaucoma. It indicates that T267384 and ENST00000564363 are highly expressed lncRNAs in glaucoma and are biomarkers that contribute to the diagnosis of glaucoma. The present invention provides a strong molecular biology basis for the diagnosis of glaucoma, and has far-reaching clinical significance and generalization performance.